A series of cardiometabolic-related news items has been observed from AstraZeneca, AbbVie, Regeneron, Ionis, GSK, and Zealand Pharma/Roche. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Roche, Novo Nordisk, Hims & Hers, Sanofi, and Amgen. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Lilly aired a new Foundayo DTC ad on social media platforms (view Reddit post); Roche’s CT-388 has been given the INN of enicepatide, which is reflected in two Ph2 studies (view CT.gov record; view CT.gov record); and the CHMP agenda for this month’s meeting (April 20-23) has been released (view here). Below, FENIX provides highlights and insights on the respective news items.
Recently, Zealand announced topline 42-week results from the Ph2 ZUPREME-1 study, which evaluated petrelintide (QW SC amylin analog) in adults with obesity or overweight (previous FENIX insight). Following the announcement, Zealand’s share price declined -36%, reflecting investor disappointment in petrelintide’s weight loss efficacy (up to -10.7%), despite an otherwise favorable tolerability profile. Below, FENIX provides a thoughts-on analysis of the topline ZUPREME-1 data, including a deep-dive on how petrelintide’s benefit/risk profile compares to other amylin analogs in development, as well as why amylin may fall short of Zealand’s expectations for it becoming the next foundational AOM.
Earlier this week on FiercePharma, an abbreviated version of FENIX’s Obesity Power Rankings was published (view article). Below is the complete version.
A series of cardiometabolic-related news items has been observed from Zealand Pharma, Novo Nordisk, Madrigal Pharmaceuticals, and Goodpath. Below, FENIX provides highlights and insights on the respective news items.
Three cardiometabolic-related news items have been observed: Roche (view press release; view slides) and Sanofi (view press release; view slides; view infographic) hosted their respective Q4 ’25 earnings calls; and Fractyl Health announced 6-month results from its REMAIN-1 Midpoint Cohort for the Revita procedure (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Roche, Lilly, Arrowhead, Argo, and Cytokinetics. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Roche, Novo Nordisk, Ascletis Pharma, BioAge Labs, and Indiana University. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Pfizer/Metsera, Zealand Pharma, WeightWatchers, Ascletis Pharma, and Lilly/Mangoceuticals (MangoRx). Below, FENIX provides highlights and insights for the respective news items, including how Zealand can use a PRV to decrease the review time of petrelintide.